Gynecological cytology, also known as the PAP test or Thin Prep, involves observing a cervical sample under a microscope in order to screen for cervical cancer. Negative results are those indicating a “negative” result, “no malignancy,” or “no intraepithelial lesions.”
Additional comments indicating inflammatory changes, atrophic vaginitis, or “consistent with repair,” “no significant atypia” or an equivalent are not associated with the risk of developing cervical cancer. With the exception of results identified as ASC-US (atypical squamous cells of unknown significance), other lesions are generally followed up by colposcopy to determine the nature of the lesion. Results identified as ASC-US indicate the mildest stage of abnormality and, if not repeated, do not require a colposcopy.
However, for women over age 30, oncogenic virus screening (HPV) is recommended. ASC-H (high-grade squamous intraepithelial lesion), LSIL (low-grade squamous intraepithelial lesion) and HSIL (high-grade squamous intraepithelial lesion) are more serious and must be confirmed with a colposcopy. A diagnosis of squamous cell carcinoma indicates that cervical cancer is present. Atypical glandular cells are also significant because they can eventually become cancerous.
Biron sets itself apart
Liquid-based Pap test for HPV and uterine cancer screening*.
More sensitive than the conventional smear testing.
Results available in 5 to 7 business days, compared to 1 to 6 months for conventional smear testing.
Molecular detection of HPV from the same sample, if necessary.